Chinese Journal of Dermatology ›› 2018, Vol. 51 ›› Issue (9): 704-707.doi: 10.3760/cma.j.issn.0412-4030.2018.09.023
Previous Articles Next Articles
Yue-Tong QIAN1,Dong-Lai MA
Received:2017-09-29
Revised:2017-10-30
Online:2018-09-15
Published:2018-08-30
Contact:
Dong-Lai MA
E-mail:mdonglai@sohu.com
Yue-Tong QIAN Dong-Lai MA. Application of Janus kinase inhibitors in dermatology[J].Chinese Journal of Dermatology, 2018, 51(9): 704-707.
| ［1］ | Hsu L, Armstrong AW. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis［J］. J Immunol Res, 2014,2014（3）:283617. doi: 10.1155/2014/283617.<br /> |
| ［2］ | Shreberk⁃Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review［J］. J Am Acad Dermatol, 2017,76（4）:745⁃753. doi: 10.1016/j.jaad.2016.12.004.<br /> |
| ［3］ | Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class［J］. J Am Acad Dermatol, 2017,76（4）:736⁃744. doi: 10.1016/j.jaad.2016.12.005.<br /> |
| ［4］ | Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo⁃controlled, phase III trials［J］. Br J Dermatol, 2015,173（4）:949⁃961. doi: 10.1111/bjd.14018.<br /> |
| ［5］ | Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate⁃to⁃severe chronic plaque psoriasis: a phase 3 randomised non⁃inferiority trial［J］. Lancet. 2015,386（9993）:552⁃561. doi: 10.1016/S0140⁃6736（14）62113⁃9.<br /> |
| ［6］ | Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase （JAK） 1/JAK2 inhibitor, in patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2016,174（6）:1266⁃1276. doi: 10.1111/bjd.14403. <br /> |
| ［7］ | Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis［J］. Br J Dermatol, 2013,169（1）:137⁃145. doi: 10.1111/bjd.12266.<br /> |
| ［8］ | Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial［J］. BMC Dermatol, 2016,16（1）:15. doi: 10.1186/s12895⁃016⁃0051⁃4.<br /> |
| ［9］ | Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis［J］. J Am Acad Dermatol, 2012,67（4）:658⁃664. doi: 10.1016/j.jaad. 2011.12.018.<br /> |
| ［10］ | Udkoff J, Waldman A, Ahluwalia J, et al. Current and emerging topical therapies for atopic dermatitis［J］. Clin Dermatol, 2017,35（4）:375⁃382. doi: 10.1016/j.clindermatol.2017.03.010.<br /> |
| ［11］ | Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate［J］. J Am Acad Dermatol, 2015,73（3）:395⁃399. doi: 10.1016/j.jaad.2015.06.045.<br /> |
| ［12］ | Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial［J］. Br J Dermatol, 2016,175（5）:902⁃911. doi: 10.1111/bjd.14871.<br /> |
| ［13］ | Liu LY, Craiglow BG, Dai F, et al. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients［J］. J Am Acad Dermatol, 2017,76（1）:22⁃28. doi: 10.1016/j.jaad.2016. 09.007.<br /> |
| ［14］ | Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition［J］. Nat Med, 2014,20（9）:1043⁃1049. doi: 10.1038/nm.3645.<br /> |
| ［15］ | Craiglow BG, Tavares D, King BA. Topical ruxolitinib for the treatment of alopecia universalis［J］. JAMA Dermatol, 2016,152（4）:490⁃491. doi: 10.1001/jamadermatol.2015.4445.<br /> |
| ［16］ | Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib［J］. J Am Acad Dermatol, 2017,76（6）:1054⁃1060. doi: 10.1016/j.jaad.2017.02. 049.<br /> |
| ［17］ | Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis⁃directed therapy［J］. JAMA Dermatol, 2015,151（10）:1110⁃1112. doi: 10.1001/jamadermatol.2015.1520.<br /> |
| ［18］ | Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata （AA） ［J］. J Am Acad Dermatol, 2016,74（2）:370⁃371. doi: 10.1016/j.jaad.2015.09.073.<br /> |
| ［19］ | Liu LY, Strassner JP, Refat MA, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure［J］. J Am Acad Dermatol, 2017,77（4）:675⁃682. doi: 10.1016/j.jaad.2017.05.043.<br /> |
| ［20］ | Hornung T, Janzen V, Heidgen FJ, et al. Remission of recalcitrant dermatomyositis treated with ruxolitinib［J］. N Engl J Med, 2014,371（26）:2537⁃2538. doi: 10.1056/NEJMc1412997.<br /> |
| ［21］ | Vesely MD, Imaeda S, King BA. Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis［J］. JAAD Case Rep, 2016,3（1）:4⁃6. doi: 10.1016/j.jdcr.2016.09.008.<br /> |
| ［22］ | Damsky W, King BA. Idiopathic erythema multiforme: evidence of underlying Janus kinase⁃signal transducer and activator of transcription activation and successful treatment with tofacitinib［J］. JAAD Case Rep, 2016,2（6）:502⁃504. doi: 10.1016/j.jdcr.2016. 10.009.<br /> |
| ［23］ | Vincenti F, Silva HT, Busque S, et al. Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients［J］. Am J Transplant, 2015,15（6）:1644⁃1653. doi: 10.1111/ajt.13181.<br /> |
| ［24］ | Samadi A, Ahmad Nasrollahi S, Hashemi A, et al. Janus kinase （JAK） inhibitors for the treatment of skin and hair disorders: a review of literature［J］. J Dermatolog Treat, 2017, 28（6）: 476⁃483. doi: 10.1080/09546634.2016.1277179.<br /> |
| [1] | Liang Yuan, Liu Lingling, Wang Shan, Zhao Zuotao, Ma Lin, Xiang Xin, Gu Heng, Chen Kun, Wang Hua, Yi Hong, Chen Jinping, Zhang Jintao, Yao Zhirong, Guo Yifeng, Chen Ji, Cheng Ying, Zhu Xuejun. Efficacy and safety of 0.03% tacrolimus ointment in the long-term intermittent maintenance treatment of atopic dermatitis in children: a multicenter randomized controlled clinical trial [J]. Chinese Journal of Dermatology, 2019, 52(8): 519-524. |
| [2] | Lu Tan, Wang Shan, Wang Liuhui, Li Ping, Shu Hong, Shen Chunping, Wu Yao, Luo Zhen, Miao Limin, Wang Hongbing, Jiao Lei, Tian Jing, Peng Xiaoxia, Zhao Mutong, Liu Ying, Nie Xiaolu, Ma Lin, He Li. An emollient containing Prinsepia utilis Royle oil extracts and other extracts for the improvement of clinical symptoms among children aged 2 - 12 years with atopic dermatitis in the remission period: a multicenter, randomized, parallel-group, controlled clinical study [J]. Chinese Journal of Dermatology, 2019, 52(8): 537-541. |
| [3] | Zhou Yuan, Chen Wei, Wang Daguang. Treatment of pincer nails [J]. Chinese Journal of Dermatology, 2019, 52(5): 364-367. |
| [4] | Yu Lijuan, Lyu Zhongfa. JAK inhibitors for the treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2019, 52(5): 343-346. |
| [5] | Lei Jiehao, Fan Qimin, Chen Rong, Xu Ai′e. Association between efficacy of and response to narrow-band ultraviolet B phototherapy as well as factors related to phototherapy response in patients with vitiligo [J]. Chinese Journal of Dermatology, 2019, 52(4): 259-262. |
| [6] | Liu Zijing, Wang Xiaoyan, Juliandri, Zhang Jiawen, Xu Yang. Non-surgical lipolysis techniques [J]. Chinese Journal of Dermatology, 2019, 52(4): 290-294. |
| [7] | Zhai Hanyue, Song Yixing. Childhood molluscum contagiosum treated with 585 nm pulsed dye laser: a clinical observation [J]. Chinese Journal of Dermatology, 2019, 52(3): 195-197. |
| [8] | Guan Xin, Zhang Chunlei. Evaluation of efficacy of infliximab in the long-term treatment of moderate and severe psoriasis vulgaris [J]. Chinese Journal of Dermatology, 2019, 52(2): 86-89. |
| [9] | . Evaluation of efficacy of microneedling radiofrequency for the treatment of facial acne scars [J]. Chinese Journal of Dermatology, 2018, 51(9): 672-675. |
| [10] | . Therapeutic effect of combined glucocorticoids on herpes zoster of the head and face in the elderly [J]. Chinese Journal of Dermatology, 2018, 51(9): 670-672. |
| [11] | Qin-Bei quanzhong liu. Efficacy of azithromycin versus doxycycline in the treatment of genital Chlamydia trachomatis infection: a meta-analysis [J]. Chinese Journal of Dermatology, 2018, 51(9): 691-695. |
| [12] | Yuan ZHOU Da-Guang Wang. Treatment of ingrown nail [J]. Chinese Journal of Dermatology, 2018, 51(8): 632-635. |
| [13] | Xiao Yuanyuan, Xu Zigang, Xu Zhe, Xiang Xin, Liu Ying, Ma Lin, Yang Zhou. Vincristine combined with glucocorticoids for the treatment of 11 cases of infantile Kasabach-Merritt syndrome [J]. Chinese Journal of Dermatology, 2018, 51(8): 601-603. |
| [14] | Jun HUANG. Application of reflectance confocal microscopy and dermoscopy in the efficacy evaluation of comprehensive treatment of melanosis [J]. Chinese Journal of Dermatology, 2018, 51(6): 440-442. |
| [15] | . Regulation of apoptosis of host cells by in vitro azithromycin-induced persistent Chlamydia trachomatis infection [J]. Chinese Journal of Dermatology, 2018, 51(5): 347-351. |
|
